ITCI Intra-Cellular Therapies Inc.

9.1
+0.07  (+1%)
Previous Close 9.03
Open 9.08
Price To Book 1.96
Market Cap 502,076,320
Shares 55,173,222
Volume 580,768
Short Ratio
Av. Daily Volume 1,334,404

NewsSee all news

  1. Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2019 Financial Results
  2. Intra-Cellular Therapies to Present at the Canaccord Genuity 39th Annual Growth Conference
  3. Intra-Cellular Therapies to Host Conference Call to Provide Regulatory Update Following Recent Meeting with FDA
  4. Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded
  5. Intra-Cellular Therapies Provides Update on FDA Advisory Committee Meeting for Lumateperone for the Treatment of Schizophrenia

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial did not meet primary endpoint - July 8, 2019.
ITI-007 - Monotherapy (Study 401)
Bipolar depression
Phase 3 interim analysis December 18, 2018 noted trial to stop due to futility.
ITI-007-201
Agitation in patients with dementia
PDUFA date extended by three months to December 27, 2019.
Lumateperone
Schizophrenia
Phase 3 enrollment to be completed 2H 2019.
ITI-007 - Adjunctive Therapy
Bipolar depression
Phase 3 trial met primary endpoint - July 8, 2019.
ITI-007 - Monotherapy (Study 404)
Bipolar depression
Phase 1/2 top-line presented October 22, 2018.
ITI-214
Parkinson's disease (PD)

Latest News

  1. Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2019 Financial Results
  2. Intra-Cellular Therapies to Present at the Canaccord Genuity 39th Annual Growth Conference
  3. Intra-Cellular Therapies to Host Conference Call to Provide Regulatory Update Following Recent Meeting with FDA
  4. Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded
  5. Intra-Cellular Therapies Provides Update on FDA Advisory Committee Meeting for Lumateperone for the Treatment of Schizophrenia
  6. Why PulteGroup, Intra-Cellular Therapies, and Clear Channel Outdoor Slumped Today
  7. Is Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Potentially Underrated?
  8. A Look At Benzinga Pro's Most-Searched Tickers For July 9, 2019
  9. Company News For Jul 9, 2019
  10. Intra-Cellular Therapies' Candidate Fails in Phase III Study
  11. Why Deutsche Bank, Intra-Cellular Therapies, and Coherus BioSciences Slumped Today
  12. Why Intra-Cellular Therapies Is Tanking Today
  13. Intra-Cellular Therapies stock down 15% after disappointing Phase 3 trial results
  14. Intra-Celluar Therapies Falls Following Results For Treatment Of Bipolar Depression
  15. UPDATE 1-Intra-Cellular drug fails one of two bipolar depression studies; shares fall
  16. Intra-Cellular announces positive results in late-stage trials of treatment for bipolar depression
  17. Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression
  18. The Week Ahead In Biotech: Conferences, Clinical Trial Readouts And Earnings
  19. Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?